Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 6
2002 3
2003 1
2004 2
2005 3
2006 5
2007 6
2008 13
2009 10
2010 11
2011 15
2012 15
2013 15
2014 6
2015 14
2016 5
2017 12
2018 8
2019 4
2020 7
2021 3
2022 2
2023 1
2024 9
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Considerations when treating influenza infections with oseltamivir.
Gu C, Chen Y, Li H, Wang J, Liu S. Gu C, et al. Expert Opin Pharmacother. 2024 Jul;25(10):1301-1316. doi: 10.1080/14656566.2024.2376660. Epub 2024 Jul 15. Expert Opin Pharmacother. 2024. PMID: 38995220 Review.
EXPERT OPINION: Oseltamivir is an oral prodrug of oseltamivir carboxylate, an influenza A and B neuraminidase inhibitor. Recently, the therapeutic efficacy of oseltamivir has been demonstrated in several trials. ...
EXPERT OPINION: Oseltamivir is an oral prodrug of oseltamivir carboxylate, an influenza A and B neuraminidase inhibitor. Recen …
Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.
Bonomini A, Zhang J, Ju H, Zago A, Pacetti M, Tabarrini O, Massari S, Liu X, Mercorelli B, Zhan P, Loregian A. Bonomini A, et al. Antiviral Res. 2024 Oct;230:105980. doi: 10.1016/j.antiviral.2024.105980. Epub 2024 Aug 6. Antiviral Res. 2024. PMID: 39117284 Free article.
In this short communication, we investigated the effects of combinations of the PA-PB1 interaction inhibitor 54 with oseltamivir carboxylate (OSC), zanamivir (ZA), favipiravir (FPV), and baloxavir marboxil (BXM) on the inhibition of influenza A and B virus replicati …
In this short communication, we investigated the effects of combinations of the PA-PB1 interaction inhibitor 54 with oseltamivir c …
Oseltamivir: a review of its use in influenza.
McClellan K, Perry CM. McClellan K, et al. Drugs. 2001;61(2):263-83. doi: 10.2165/00003495-200161020-00011. Drugs. 2001. PMID: 11270942 Review.
Oseltamivir is a prodrug of oseltamivir carboxylate (Ro 64-0802, GS4071), a potent and selective inhibitor of the neuraminidase glycoprotein essential for replication of influenza A and B viruses. ...CONCLUSIONS: Oseltamivir is a well tolerated orally active neurami …
Oseltamivir is a prodrug of oseltamivir carboxylate (Ro 64-0802, GS4071), a potent and selective inhibitor of the neuraminidas …
[Hypothermic Action of Oseltamivir Not Dependent on Its Anti-influenza Virus Action].
Ono H. Ono H. Yakugaku Zasshi. 2019;139(5):767-781. doi: 10.1248/yakushi.18-00191. Yakugaku Zasshi. 2019. PMID: 31061347 Free article. Review. Japanese.
Oseltamivir was found to target the ion channels of nicotinic acetylcholine receptors, as demonstrated by patch clamp experiments with cells expressing the human alpha3beta4 nicotinic receptor. Metabolized oseltamivir carboxylate, which inhibits the influenza virus …
Oseltamivir was found to target the ion channels of nicotinic acetylcholine receptors, as demonstrated by patch clamp experiments with cells …
Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.
Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R. Smith JR, et al. Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1. Adv Ther. 2011. PMID: 22057727 Free PMC article. Review.
The article reviews the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate, including information on special populations such as children and elderly adults, and the co-administration of oseltamivir with other agents. ...
The article reviews the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate, including informat …
Oseltamivir: a clinical and pharmacological perspective.
Doucette KE, Aoki FY. Doucette KE, et al. Expert Opin Pharmacother. 2001 Oct;2(10):1671-83. doi: 10.1517/14656566.2.10.1671. Expert Opin Pharmacother. 2001. PMID: 11825310 Review.
Oseltamivir is the ethyl ester prodrug of the antiviral molecule, oseltamivir carboxylate, a potent and selective inhibitor of influenza A and B neuraminidase (NA) (sialidase). It is highly bioavailable in capsule and suspension formulations and, after conversion to …
Oseltamivir is the ethyl ester prodrug of the antiviral molecule, oseltamivir carboxylate, a potent and selective inhibitor of …
Oseltamivir dosing in premature infants.
McPherson C, Warner B, Hunstad DA, Elward A, Acosta EP. McPherson C, et al. J Infect Dis. 2012 Sep 15;206(6):847-50. doi: 10.1093/infdis/jis471. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807525 Free PMC article. Clinical Trial.
Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n=8) resulted in oseltamivir carboxylate exposure comparable to previously published pediatric data, which helps prospectively validate this regimen. Oseltamivir 3 mg/kg/dose once daily …
Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n=8) resulted in oseltamivir carboxylate expos …
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Davies BE. Davies BE. J Antimicrob Chemother. 2010 Apr;65 Suppl 2(Suppl 2):ii5-ii10. doi: 10.1093/jac/dkq015. J Antimicrob Chemother. 2010. PMID: 20215135 Free PMC article. Review.
Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infect …
Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active meta …
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Widmer N, et al. Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923248 Review.
A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in influenza patients has not yet been demonstrated; thus no formal therapeutic or toxic range can be proposed. ...However, there is a lack …
A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in infl …
Antivirals for the treatment and prevention of epidemic and pandemic influenza.
Oxford JS. Oxford JS. Influenza Other Respir Viruses. 2007 Jan;1(1):27-34. doi: 10.1111/j.1750-2659.2006.00006.x. Influenza Other Respir Viruses. 2007. PMID: 19453477 Free PMC article. Review.
Oseltamivir, the most widely used NI, is administered orally as a prodrug (oseltamivir carboxylate) and systemically distributed to all potential infection sites. Zanamivir, a second NI, is administered by inhalation via a disk inhaler and deposited primarily in the …
Oseltamivir, the most widely used NI, is administered orally as a prodrug (oseltamivir carboxylate) and systemically distribut …
158 results